ArticleThe Journal of international medical research2026
Primary testicular neuroendocrine tumor: Diagnostic challenges and WHO 2022 classification insights.
Article in The Journal of international medical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary testicular neuroendocrine tumors are exceedingly rare, comprising less than 1% of testicular neoplasms. Their nonspecific presentation and overlap with other testicular tumors make diagnosis challenging. We report the case of a 21-year-old male with a painless left testicular mass. Imaging revealed a hypervascular lesion with calcifications, while serum markers (alpha-fetoprotein, beta-human chorionic gonadotropin, and lactate dehydrogenase) were normal. Radical orchiectomy demonstrated a 3-cm well-circumscribed tumor composed of monotonous cells with "salt-and-pepper" chromatin and low mitotic activity. Immunohistochemistry confirmed neuroendocrine differentiation (synaptophysin, chromogranin, INSM1 positive; Ki-67 < 1%). This profile established the diagnosis of a well-differentiated testicular neuroendocrine tumor, classified under the 2022 WHO framework as "prepubertal-type." Although indolent, these tumors require long-term follow-up due to the risk of late metastasis. Radical orchiectomy remains the treatment of choice. This case emphasizes the critical role of histopathology and immunoprofiling in diagnosis and contributes to refining the clinical understanding of this rare entity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.